Literature DB >> 2208160

Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening.

D J Zhou1, D Pompon, S A Chen.   

Abstract

A mammalian cell expression plasmid, pH beta-Aro, containing the human placenta aromatase complementary DNA was constructed. The prepared plasmid was used to transfect breast cancer cells (MCF-7), noncancerous breast cells (HBL-100), and Chinese hamster ovary cells by a stable expression method. While the maximum velocities for aromatase expressed in three types of cells were different (10-201 pmol of [3H2O] formed/h/mg) using [1 beta, 2 beta-3H]androst-4-ene-3,17-dione as the substrate, the apparent Michaelis-Menten constants were found to be similar (39.9-57.8 nM) and were within the range determined for the enzyme existing in human placenta. The expressed activities were inhibited by the known aromatase inhibitors, 4-hydroxyandrostenedione and aminoglutethimide, at concentrations that normally inhibit the human placental aromatase. However, it was found that the inhibition profiles were different for aromatase expressed in different types of cells, suggesting that other factors, such as the uptake of the inhibitor, may also play a role in determining the inhibition efficiency. These constructed aromatase expressing mammalian cell lines will be very useful tools for aromatase inhibitor screening.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208160

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.

Authors:  Shiuan Chen; Jingjing Ye; Ikuko Kijima; Dean Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

3.  COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.

Authors:  Bin Su; Xiaohan Cai; Yanyan Hong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-11       Impact factor: 4.292

Review 4.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

5.  Aromatase and breast cancer.

Authors:  A Brodie; G Sabnis; D Jelovac
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

6.  Moving Toward Integrating Gene Expression Profiling Into High-Throughput Testing: A Gene Expression Biomarker Accurately Predicts Estrogen Receptor α Modulation in a Microarray Compendium.

Authors:  Natalia Ryan; Brian Chorley; Raymond R Tice; Richard Judson; J Christopher Corton
Journal:  Toxicol Sci       Date:  2016-02-10       Impact factor: 4.849

7.  HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.

Authors:  Gauri J Sabnis; Olga G Goloubeva; Armina A Kazi; Preeti Shah; Angela H Brodie
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

8.  Aromatase resistance mechanisms in model systems in vivo.

Authors:  Angela Brodie; Luciana Macedo; Gauri Sabnis
Journal:  J Steroid Biochem Mol Biol       Date:  2009-09-22       Impact factor: 4.292

9.  The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.

Authors:  Xin Wang; Selma Masri; Sheryl Phung; Shiuan Chen
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

10.  Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.

Authors:  Gauri Sabnis; Olga Goloubeva; Rabia Gilani; Luciana Macedo; Angela Brodie
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.